Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2E1 | P05181 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22199088 | 0.77 | CYP2E1 (0.54) | CYP2E1CYP2A6KDM4ESMN1; SMN2CYP17A1 | |
| SCHEMBL22185839 | 0.76 | CPB2 (0.44) | ALDH1A1SMN1; SMN2EGLN2 | |
| SCHEMBL22184964 | 0.75 | CYP2A6 (0.66) | CYP2E1CYP2A6 | |
| SCHEMBL22185891 | 0.75 | RPS6KA5 (0.33) | CYP2E1CYP2A6CYP17A1 | |
| SCHEMBL22184875 | 0.74 | CYP3A4 (0.33) | — | |
| SCHEMBL22185905 | 0.72 | APLNR (0.35) | — | |
| SCHEMBL24495988 | 0.71 | CYP2E1 (0.41) | CYP2E1CYP2A6CYP1A2 | |
| SCHEMBL22185892 | 0.70 | TRPV1 (0.34) | CYP2E1CYP2A6KDM4ECYP17A1 | |
| SCHEMBL22184960 | 0.70 | PANK3 (0.37) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL11901185 | 0.70 | GCG (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200206233-A1 | HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2020-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200206233-A1 | HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS | IDH1, IDH2, IDH3A | CYP2E1 249/4885CYP2A6 1375/4885KDM4E 936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.